Abstract
Three physicians and 4 pharmacists address a controversy: should parenteral phenytoin products be used for patients who present with seizure clusters that fall short of full-blown status epilepticus? To aid in the decision-making process, this manufacturer-supported panel developed an algorithm that attempts to balance the lower adverse-side-effect profile of fosphenytoin against the lower cost of phenytoin. The incidence of serious adverse events is probably …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
